Phase 2 Interstitial Lung Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People whose tumour tissue and/or blood samples show a mutation in the BRAF gene, found at any point during treatment or follow-up
- People whose disease has not responded to, or has come back after, standard first- and second-line treatments (such as Vinblastine, prednisolone, Cytosine Arabinoside, or Cladribine), with specific requirements around how many cycles or weeks of those treatments were completed (confirm with trial site)
- People whose disease has come back for a third time or more, with or without involvement of high-risk organs
- People whose disease has returned after completing a course of Vemurafenib treatment
- People who have shown signs of a neurodegenerative condition on a brain or spinal cord MRI scan
- People who have signed informed consent to take part in the trial, including consent to receive Vemurafenib, in line with current legal requirements
- People of pubertal or reproductive age who agree to use effective contraception throughout the Vemurafenib treatment period and for at least one year after it ends
- People who are already enrolled in the related HISTIOGEN trial
Who may not be able to join:
- People who are pregnant or currently breastfeeding
- People who have a known allergy or sensitivity to the study drug or any of its components
- People with certain eye conditions, including inflammation of the iris or middle eye (iritis or uveitis), or a blockage of the veins in the retina
- People who are currently taking other medications that may interact with Vemurafenib
- People who still have significant side effects from a previous treatment that would make it unsafe to receive Vemurafenib
- People who have been diagnosed with another type of cancer before joining the study
- People with other serious ongoing health conditions, abnormal test results, or other factors that the trial doctor considers may increase risks or affect the trial's results (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Anna Raciborska, Mother and Child Institute
Phone: +48 22 32 77 205
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
event-free survival
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.